Data gathered: July 15
Alternative Data for Kazia Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 1,000 | Sign up | Sign up | Sign up |
| Google Trends | 5 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 178 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 6,492 | Sign up | Sign up | Sign up |
| Twitter Followers | 932 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| Youtube Subscribers | 273 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 14 | Sign up | Sign up | Sign up |
About Kazia Therapeutics
Kazia Therapeutics KZIA is an Australia-based clinical-stage company focused on developing drugs targeting oncology indications.
| Price | $11.43 |
| Target Price | Sign up |
| Volume | 152,540 |
| Market Cap | $15M |
| Year Range | $3.09 - $33.9 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Novogen (NASDAQ:KZIA) Raised to “Sell” at Wall Street ZenJuly 13 - ETF Daily News |
 |
Novogen (NASDAQ:KZIA) Upgraded at HC WainwrightJuly 12 - ETF Daily News |
|
Novogen (NASDAQ:KZIA) Trading 39.7% Higher – Should You Buy?July 9 - ETF Daily News |
 |
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b TrialJuly 8 - Yahoo |
|
Maxim Group Reiterates “Buy” Rating for Kazia Therapeutics (NASDAQ:KZIA)June 12 - ETF Daily News |
|
Kazia Therapeutics First Half 2025 Earnings: AU$12.29 loss per share (vs AU$18.40 loss in 1H 2024)June 12 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 2.5M | 0 | 2.5M | -18M | -19M | 0.000 |
| Q2 '24 | 0 | 0 | 0 | 0 | 0 | 0.000 |
| Q4 '23 | 5 | 0 | 5 | -8.8M | -7.9M | |
| Q3 '23 | 560 | 0 | 560 | -6.9M | -9.6M | |
| Q2 '23 | 0 | 0 | 0 | 0 | 0 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Kazia Therapeutics (KZIA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Kazia Therapeutics?
The Market Cap of Kazia Therapeutics is $15M.
What is the current stock price of Kazia Therapeutics?
Currently, the price of one share of Kazia Therapeutics stock is $11.43.
How can I analyze the KZIA stock price chart for investment decisions?
The KZIA stock price chart above provides a comprehensive visual representation of Kazia Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Kazia Therapeutics shares. Our platform offers an up-to-date KZIA stock price chart, along with technical data analysis and alternative data insights.
Does KZIA offer dividends to its shareholders?
As of our latest update, Kazia Therapeutics (KZIA) does not offer dividends to its shareholders. Investors interested in Kazia Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Kazia Therapeutics?
Some of the similar stocks of Kazia Therapeutics are Novartis, Illumina, Regeneron, Vertex Pharmaceuticals, and West Pharmaceutical Services.
.